Follow last change Jul 2020 re-read 2 minutes ago

C3F8

also known as perfluoropropane

Developed for: macular holes · retinal vascular disorder · wet macular degeneration
Investigated by: Federal University of Pernambuco · King's College Hospital NHS Trust

today NCT04527848 · Ph 4 NCT01835067 · Ph 2/3

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/31 trial
Phase 2/3	NCT01835067	Sep 2014 → Nov 2019	retinal vascular disorder, wet macular degeneration	King's College Hospital NHS Trust	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT04527848	May 2016 → Jul 2020	macular holes	Federal University of Pernambuco	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT00673296 Background	Jan 2007 → Apr 2008	diabetic retinopathy	National Taiwan University Hospital	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	C3F8	“receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting” NCT00673296 ↗ 2 NCT01835067 ↗ NCT04527848 ↗
Known as	perfluoropropane	“utilizing a small amount of undiluted C3F8 (perfluoropropane) versus a large amount of diluted C3F8 versus a small amount of undiluted SF6 (sulfur hexafluoride)” NCT04527848 ↗
Modality	Other / unclassified	“intraocular gas injection” NCT04527848 ↗
Route	Intravitreal	“receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL) during the same setting” NCT00673296 ↗